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RESUMO  
O tremor essencial é uma perturbação neurológica reconhecida como uma das mais 
comuns doenças do movimento e que pode ser incapacitante e repercutir-se 
negativamente na qualidade de vida dos doentes. A abordagem do tremor essencial deve 
ser ajustada ao grau de incapacidade do doente e o actual tratamento é primariamente 
farmacológico, enquanto procedimentos cirúrgicos são reservados para casos mais 
graves e refractários. Ainda assim, muitos doentes são mal controlados e revisões da 
literatura apontam uma escassez de estudos direccionados à terapêutica no tremor 
essencial, o que resulta num limitado número de normas de orientação clínica (NOC’s) 
para o tratamento desta perturbação. Este artigo tem como objectivo realizar uma 
pesquisa sistemática da literatura para identificar todas as NOC’s disponíveis dirigidas 
ao tratamento do tremor essencial, quer internacionais quer regionais, para avaliar a sua 
qualidade metodológica usando o instrumento Appraisal of Guidelines for Research and 
Evaluation II (AGREE II). Também se pretende extrair as principais recomendações 
sobre este tópico e comparar a sua consistência. Este artigo visa beneficiar o futuro 
desenvolvimento de NOC’s sobre tratamento do tremor essencial que tenham superior 
qualidade metodológica.  
ABSTRACT 
Essential tremor (ET) is a neurological disorder widely recognized as one of the most 
common movement disorders and can sometimes be disabling, negatively affecting 
patient’s life quality. ET approach should be adjusted to patient’s degree of disability 
and current management is primarily pharmacological, while surgical procedures are 
usually reserved for more severe and refractory cases. Nonetheless, many patients are 
poorly controlled and reviews of the literature have emphasized the paucity of studies 
targeted at analyzing treatment options for ET, which in turn results in a limited number 
of clinical practice guidelines for the treatment of this disorder. The purpose of this 
study is to systematically identify all available international and regional guidelines 
addressing ET treatment and evaluate their methodological quality using the AGREE II 
instrument. Another objective is to extract key recommendations on this subject and 
compare their consistency. This article aims to benefit the future development of 
guidelines concerning the treatment of ET with superior methodological quality. 
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BACKGROUND 
Essential tremor is a neurodegenerative disorder that is widely recognized as one of the 
most common adult-onset movement disorders. 
1-5 
A meta-analysis from 2010 used 
population-based studies (n = 28) to estimate that the age independent pooled 
prevalence of ET was 0.9% and established an increasing prevalence with age 
(prevalence being 4.6% for individuals ≥ 65 years old).1,6 
Classically, it is clinically characterized by bilateral, largely symmetrical, postural 
(which manifests during voluntary maintenance of a position against gravity) and/or 
kinetic (revealed with voluntary movement) tremor involving the upper limbs (in at 
least 95% of patients) and less commonly the head, face/jaw, voice, tongue, trunk, and 
lower limbs, in the absence of other neurologic signs.
7-9
 
However, ET is a heterogeneous disorder and there is little agreement regarding both 
clinical definition and diagnostic criteria.
10,1 
Moreover, besides the described action 
tremor, patients may manifest intention tremor 
12
, rest tremor,
13
 and ataxia
14
. In addition 
to these motor signs, it has been suggested an increased risk for neuropsychiatric 
manifestations such as cognitive impairment, dementia, 
15,16 
depression and personality 
disorders. 
17
 
The underlying pathophysiological mechanisms are still not well elucidated.  
Nonetheless, the fundamental abnormality in ET is an abnormal motor unit entrainment 
at frequencies of 4–12 Hz.
18
 Substantial clinical, neuroimaging and neurophysiological 
data support the hypothesis that this motor unit entrainment emerges from neuronal 
oscillation in the cortico-bulbo-cerebello-thalamo-cortical loop network but the cause 
for oscillation in ET is unknown.
19-23
 
Genetic susceptibility has a long been identified as having significant role in essential 
tremor. 
24
 There is a positive family history in at least 50-70% of cases and transmission 
is thought to be autosomal dominant, with high genetic penetrance by age of 65 
years.
25,26
 
Although presumably thought to not affect life expectancy, the diagnostic term “benign 
essential tremor” has been appropriately decommissioned with the growing appreciation 
that ET often produces substantial social or physical disability.
27, 28
 Affected patients 
represent a heterogeneous population and severe cases could be very disabling.
29
 ET is 
usually progressive and patients may experience difficulties performing basic daily 
activities, thereby impairing quality of life.
27
 Furthermore, 90% of patients who seek 
medical care report disability and severely affected end-stage patients are unable to feed 
or dress themselves. 15–25% of patients are forced to retire prematurely, and 60% 
choose not to apply for a job or promotion because of uncontrollable shaking.
30
 
ET approach should be tailored to patient’s degree of disability. Current management is 
primarily pharmacological, aimed to improve function and limit embarrassment caused 
by ET, while surgical procedures are reserved for more disabling cases. 
31
 Despite the 
high prevalence of this disorder and many patients poorly controlled, there is a lack of 
published recommendations focused on establishing and regulating its treatment. 
Furthermore, systematic reviews of the literature have emphasized a paucity of studies 
targeted at analyzing additional and current pharmacological and surgical treatments for 
ET. An explanation relies on scarce interest of the pharmaceutical industry in 
developing new drugs and to perform expensive clinical trials with adequate 
methodology on old drugs. 
32
 
In order to assist physicians and patient decisions on specific circumstances, clinical 
practice guidelines (CPG) were developed as tools that convey scientific evidence into 
clinical practice with the ultimate goal of improving healthcare quality. 
33 
To ensure that 
CPGs can meet this goal, internationally recognized, valid, reliable and feasible 
standards should be developed to assess the quality of guidelines and to promote their 
rigorous development.
34,35
 
Accordingly, the Appraisal of Guidelines for Research and Evaluation II (AGREE II) 
instrument is a validated tool that has been endorsed by leading producers, raters and 
compilers of international CPGs to provide a framework to assess the methods used by 
the guideline developers.
36
 To our knowledge, there are no published assessments of 
guideline quality for ET treatment. 
Our purpose is to identify international or regional guidelines addressing ET treatment 
and evaluate their methodological quality using the AGREE II instrument. A secondary 
objective is to extract the recommendations stated on the guidelines and compare their 
consistency. This article is targeted to neurologists or other physicians who deal with 
ET on a regular basis in their clinical practice. Additionally, it may be valuable to 
former or future guideline developers concerning the treatment of Essential Tremor, in 
order to improve methodological strategies. 
METHODS 
The methods used in this appraisal were structured in phases: searching for guidelines, 
applying selection criteria, evaluating guideline quality, extracting recommendations 
and grouping them into standardized categories for comparison across guidelines. 
Search strategy 
A systematic literature search was conducted to identify evidence-based clinical practice 
guidelines for ET treatment. The National Guideline Clearinghouse, PubMed, 
MEDLINE, Cochrane Database of Systematic Reviews, National Institute for Health 
and Care Excellence (NICE), Guidelines International Network (G-I-N) and Web of 
Science databases were searched. Homepages of international medical societies and 
institutions were also screened for current CPG publications.  
In addition, neurologists with expertize on tremor from different countries amongst 
members of the International Parkinson and Movement Disorder Society (MDS-PAS) 
were consulted and questioned whether they were aware existing national or regional 
CPG on ET treatment. Starting from 30
th
 March 2015, a total of 570 physicians were 
contacted with individually addressed e-mails from which 83 replies were attained. 
Eligibility criteria 
We considered published documents with systematically developed recommendations 
on treatment of essential tremor.
37
 
Precise pre-defined selection criteria were applied to identify articles eligible for quality 
appraisal (Appendix 1). To upturn the number of guidelines attained no exclusion 
criteria based on language or publication date were defined. Research articles, 
guidelines for use in clinical trials and systematic reviews were excluded. No ethics 
approval was needed considering the systematic critical appraisal nature of this article. 
Methodological quality appraisal of the included guidelines 
The guidelines were evaluated using the AGREE II instrument.
38
 This refined tool 
provides criteria to appraise the quality of clinical practice guidelines 
38
 and consists of 
23 key items organized within 6 domains followed by an overall quality assessment of 
every guideline: 1) scope and purpose: overall objectives of the guideline, target 
population and health question; 2) stakeholder involvement: guideline development 
process and preferences of target population; 3) rigor of development: the process to 
assemble and resume evidence, the recommendation development process and its 
updating tools; 4) clarity of presentation: language, structure and format of CPG; 5) 
applicability: looking at barriers and facilitation to implementation, strategies to 
improve uptake; 6) editorial independence: pointing biases resulting from competing 
interests.
39 
Each item, including the global rating item, is rated on a scale ranging from 
strongly disagree (1) to strongly agree (7) and the assigned score is based on the item’s 
completeness and quality, increasing as more criteria and considerations detailed on the 
AGREE II manual were met. If the guideline had no relevant information on a certain 
item, it was rated as 1. 
At the end of each appraisal, the evaluator has to make a judgment as to the overall 
quality of the guideline by again giving a score from 1 to 7 and defining if the guideline 
is recommended for use, recommended for use but with modifications, or not 
recommended for practice. 
The guidelines were independently rated by 4 evaluators (RS, GD, CS and CS), after 
studying the AGREE II user manual
39
 and using the online training tool found on the 
Resource Centre of the AGREE website
40
 When necessary, appraisers had support from 
senior assistants with experience applying the AGREE II instrument. An inter-appraiser 
scores concordance on each domain was addressed and the attained standard deviation 
amongst evaluators for each item was less than 2,00 with a low discrepancy. 
Standardized domain scores are calculated by summing up all scores of the individual 
items in a domain and by scaling the total as a percentage of the maximum possible 
score for that domain.
39
  
Although the domain scores are useful for comparing guidelines and will inform 
whether a guideline should be recommended for use, the AGREE Consortium does not 
set minimum scores to differentiate between high quality and poor quality guidelines. 
39
 
These decisions should be guided by the context in which AGREE II is being used and 
in this paper we considered a domain score greater than 60% as effectively addressed. 
Thus, a guideline was labelled as recommended if at least three out of the six domains, 
including rigour of development (domain 3), were effectively addressed. 
41
 Guidelines 
were recommended with modifications if four domains scored between 30 and 60%, or 
two domains scored higher than 60%. If four domains scored less than 30%, the 
guideline was considered as not recommended for use in clinical practice.  
Extraction of the guidelines’ recommendations  
In addition to appraising the methodological quality of CPGs, recommendations for 
treatment of Essential Tremor were identified for data extraction. This analysis was 
independently performed by two members from the development group (RS and GD). 
The existence of a grading system to stratify the level of evidence was sought out in 
each CPG and if present its’ source was registered and scrutinized for further strength of 
recommendation correspondence.  
A chart was created to summarize the key characteristics of the selected guidelines: 
guideline developers; year; language, funding, addressed disorders, focus of guideline, 
target population and users, and existence of a grading system to stratify the level of 
evidence. (Table 1) 
Recommendations were only extracted if the level of evidence or the strength of 
recommendations were clearly described for each recommendation. If the authors only 
provide the level of evidence, the extraction would only be carried out if it was obvious 
to infer the degree of recommendation. Extracted recommendations were grouped 
considering the form of essential tremor (limb, head, voice) and further divided between 
pharmacological and surgical treatments. 
  
RESULTS 
Search results  
The overall search and guideline selection process is illustrated in the following 
diagram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Searching and selecting guidelines flow diagram  
Studies identified through databases 
and homepages of international 
medical societies and institutions 
(n = 196) 
Records after first screening and removed duplicates (n = 21) 
Guidelines identified through 
contacts from MDS-PAS members 
(n = 6) 
Excluded based on title 
and abstract (n = 173) 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Sc
re
en
in
g 
Id
en
ti
fi
ca
ti
o
n
 
Full text articles assessed for 
eligibility (n = 8) 
Full text articles excluded (n=13) 
- Article was exclusively a 
literature review (n=12) 
- Task force summery  
report (n=1) 
Guidelines already included 
(n = 4) 
Guidelines with ongoing 
translation process or awaiting 
appraisal. They will be included in 
the final study (n=4) 
Regarding MDS contacts via email most replies revealed inexistence of local 
recommendations or were only translations from the AAN guidelines. This consultation 
resulted in identification of CPG from Sweden, Germany and Japan, all of which were 
written in the respective native languages. 
After screening, eight publications 
42-49 
were eligible for this critical appraisal. 
Table 1: Characteristics of selected guidelines 
AAN: American Academy of Neurology; AIAN: Annals of Indian Academy of Neurology; DISMOV-SIN: Italian Movement 
Disorders Association; DGN: German Society of Neurology; SWEMODIS: Swedish Movement Disorders Society; JSNT: 
Japanese Society of Neurological Therapeutics. CAN: Chinese Association of Neurology; NS: not stated 
Evaluation of guidelines  
The methodological quality assessment for each domain is provided in Table 2. Scores 
ranged from 2,78%-92,59% across all the evaluated guidelines. Two guidelines
43,45
 
were considered as “Recommended” since more than three domains scored over 60%. 
One guideline
42
 was considered “Recommended with modifications” while one 
44
 was 
“Not Recommended”. 
  
Developer Year Language Funding Addressed disorders 
Focus of 
guideline 
Target 
population 
Target users 
Grading system to 
stratify the level of 
evidence 
AAN42 2005 English NS Essential Tremor 
Practice 
parameter 
Patients 
with ET 
Physicians, 
neurologists 
American Academy of 
Neurology system 
AAN43 2011 English 
Yes, by 
AAN 
Essential Tremor 
Update previous 
practice 
parameter 
Patients 
with ET 
Physicians, 
neurologists 
American Academy of 
Neurology system 
AIAN44 2011 English NS Essential Tremor Management 
Patients 
with ET 
NS 
American Academy of 
Neurology system 
DISMOV-
SIN45 
2013 English 
Yes, by  
DISMOV-
SIN 
Essential Tremor 
Systematic 
review, treatment 
recommendations 
Patients 
with ET 
Physicians GRADE system 
SWEMODI46 2014 Swedish NS 
Drug induced tremor, 
Essential tremor, 
Orthostatic tremor, 
Dystonic tremor, 
Parkinson's disease 
Cerebellar tremor 
Diagnosis 
Management 
Patients 
with 
tremor 
Healthcare 
professionals 
NS 
DGN47 2012 German       
JSNT48 2011 Japanese       
CAN49 2009 Chinese       
Table 2: Domain scores of the CPGs assessed using the AGREE II instrument (scores 
>60% are highlighted in green) 
Domain 1. Domain 2. Domain 3. Domain 4. Domain 5. Domain 6.
Scope and 
Purpose
Stakeholder 
Involvement
Rigor of 
Development
Clarity of 
Presentation
Applicability
Editorial 
Independence
AAN 2005 72,22% 53,70% 55,56% 92,59% 2,78% 25,00%
Recommended with 
modifications
AAN 2011 66,67% 57,41% 61,11% 87,04% 5,56% 86,11% Recommended
AIAN 2011 24,07% 14,81% 13,19% 75,93% 5,56% 36,11% Not Recommended
DISMO V-SIN 
2013
96,30% 51,85% 84,03% 92,59% 5,56% 58,33% Recommended
SWEMO DIS 
2014
DGN 2012
JSNT 2011
CAN 2009
Mean 64,82% 44,44% 53,47% 87,04% 4,87% 51,39%
Standard 
deviation
30,05% 19,89% 29,55% 7,85% 1,39% 26,98%
CPG Result
 AAN: American Academy of Neurology; AIAN: Annals of Indian Academy of Neurology; DISMOV-SIN: Italian Movement 
Disorders Association; DGN: German Society of Neurology; SWEMODIS: Swedish Movement Disorders Society; JSNT: 
Japanese Society of Neurological Therapeutics. CAN: Chinese Association of Neurology; NS: not stated 
Domain 1: Scope and Purpose. This domain had a mean score of 64,81% ± 30,05%. 
The guideline from the Italian Movement Disorders Association scored the highest at 
96,3%. Lowest score (24,07%) was addressed by Annals of Indian Academy of 
Neurology guideline. 
Domain 2: Stakeholder Involvement. All guidelines scored under 60% with a mean 
score of 44,44% ± 19,89%. 
Domain 3: Rigor of Development. The mean score was 53,47% ± 29,55%. The 
guideline from the Italian Movement Disorders Association scored the highest at 
84,03%. Lowest score (13,19%) was addressed by Annals of Indian Academy of 
Neurology guideline. 
Domain 4: Clarity of Presentation. All guidelines scored above 60%, ranging from 
75,93% to 92,56%. The mean score was 87,04 % ± 7,85%. 
Domain 5: Applicability. All guidelines scored under 10% with a mean score of 4,87% 
± 1,39%. 
Domain 6: Editorial Independence. The mean score was 51,39% ± 26,98%. The 
guideline from 2011 by the American Academy of Neurology scored the highest at 
86,11%. Lowest score (25%) was also addressed by the American Academy of 
Neurology on their guideline from 2005. 
Clarity of Presentation (87,04% ± 7,85%.) was the highest rated domain and the one 
effectively addressed by all evaluated guidelines. Scope and purpose (64,81% ± 
30,05%) was effectively addressed by most guidelines. 
On the other hand, Stakeholder Involvement (44,44% ± 19,89%.) and Applicability 
(4,87% ± 1,39%) were not effectively addressed by none of the appraised guidelines.  
Appendix 2 details the individual scores each of the 23 items of the different domains 
graded by the evaluators, by averaging the scores from each of the 4 appraisers.  
Strength of recommendation’s correspondence  
Standardized categories were made for equal comparison of the strength of 
recommendations across guidelines (Figure 2). These categories were adapted from the 
grading system used by the BMJ Clinical Evidence, using the labels: “beneficial”, 
“likely to be beneficial”, “trade-off between benefits and harms”, “likely to be 
ineffective or harmful” and “unknown effectiveness” for each intervention (Appendix 
3). 
BMJ Clinical Evidence developed these categories of effectiveness from one of the 
Cochrane Collaboration's products.
50 
Fitting interventions into these categories is not 
always straightforward and the categories represent a combination of several 
hierarchies: the size of benefit (or harm), the strength of evidence (randomized clinical 
trials or observational data), and the degree of certainty around the finding (represented 
by the confidence interval).
51,52
 
The categories took into consideration that guidelines had different scoring systems 
such that any recommendation was put in an equivalent category than it had in the 
original guideline. 
 
Figure 2. Standardised categories and correspondence for equal comparison of 
recommendations across guidelines 
  
Guidelines 
AAN 2005 
AAN 2011 
AIAN 2011 
DISMOV-SIN 
2013 
Translation of Evidence to 
Recommendation Level 
Level A established 
Level B probably 
Level C possibly 
Level U insufficient evidence 
Not recommended 
  
Strong recommendation 
 A high quality evidence 
Strong recommendation 
 B moderate quality evidence 
Strong recommendation 
 C low quality evidence 
Strong recommendation 
 D very low quality evidence 
Weak recommendation 
 A high quality evidence 
Weak recommendation 
 B moderate quality evidence 
Weak recommendation 
 C low quality evidence 
Weak recommendation 
 D very low quality evidence 
Not recommended 
 GRADE system adaptation 
Categories of effectiveness 
(BMJ clinical evidence data)  
Beneficial 
Likely to be beneficial 
Trade-off between 
benefits and harms 
Unknown effectiveness 
Likely to be ineffective 
or harmful 
Guidelines Recommendations 
Table 3 summarizes the recommendations concerning essential tremor treatment 
included in the guidelines. Four guidelines 
42-45
 had their strength of recommendations 
provided by the developers. One guideline 
46 
was excluded from data extraction because 
no grading system was given in the article. Three guidelines have ongoing translation 
processes
47-49
 
The recommendations formulated by these guidelines were categorized considering the 
form of tremor targeted in each recommendation – limb tremor, head tremor, voice 
tremor – and further organized based on pharmacological and surgical treatments. 
Table 3: Selected guideline summary of recommendations 
 
Guideline Developer 
AAN  
200542 
AAN update 
 201143 
AIAN 
201144 
DISMOV-
SIN 2013 45 
DGN 
2012 47 
JSNT 
201148 
CAN 
2009 49 
Limb Tremor 
Pharmacologic treatment  
β-blockers  
Propranolol Beneficial Beneficial Beneficial Beneficial    
Propranolol LA Beneficial Beneficial Beneficial Beneficial    
Sotalol Likely beneficial Likely beneficial Likely beneficial2 Likely beneficial2    
Atenolol Likely beneficial Likely beneficial Likely beneficial2 
Trade-off between 
benefits / harms2 
   
Nadolol 
Trade-off between 
benefits / harms 
Trade-off between 
benefits / harms 
Likely beneficial2 
Trade-off between 
benefits / harms2 
   
Metoprolol 
Unknown 
effectiveness 
Unknown 
effectiveness 
 
Trade-off between 
benefits / harms2 
   
Pindolol 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
 
Likely ineffective 
or harmful 
   
Arotinolol    Likely beneficial2    
Timolol    
Trade-off between 
benefits / harms2 
   
ICI 118.551    
Trade-off between 
benefits / harms2 
   
LI32-468    
Trade-off between 
benefits / harms2 
   
Bufetolol    
Trade-off between 
benefits / harms2 
   
Oxprenolol    
Trade-off between 
benefits / harms2 
   
Indenolol    
Trade-off between 
benefits / harms2 
   
Anticonvulsants  
Primidone Beneficial Beneficial Beneficial Beneficial    
Topiramate Likely beneficial Likely beneficial Likely beneficial2 Beneficial    
Gabapentin Likely beneficial Likely beneficial Likely beneficial2 Likely beneficial2    
Gabapentin  
(adjunct therapy) 
Unknown 
effectiveness 
Unknown 
effectiveness 
     
Phenobarbital 
Unknown 
effectiveness 
Unknown 
effectiveness 
 
Likely ineffective 
or harmful 
   
Acetazolamide 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
     
Zonisamide  
Unknown 
effectiveness 
Trade-off between 
benefits / harms2 
Likely beneficial2    
Levetiracetam  
Likely ineffective 
or harmful 
 
Likely ineffective 
or harmful 
   
Pregabalin  
Unknown 
effectiveness 
Likely beneficial2 
Likely ineffective 
or harmful 
   
Progabide    
Likely ineffective 
or harmful 
   
BarbiturateT2000    
Likely ineffective 
or harmful 
   
Benzodiazepines  
Alprazolam 
Trade-off between 
benefits / harms 
Trade-off between 
benefits / harms 
Trade-off between 
benefits / harms2 
Likely beneficial2    
Clonazepam 
Trade-off between 
benefits / harms 
Trade-off between 
benefits / harms 
Trade-off between 
benefits / harms2 
Likely ineffective 
or harmful 
   
Lorazepam   
Trade-off between 
benefits / harms2 
    
Diazepam   
Trade-off between 
benefits / harms2 
    
Neuroleptics  
Clozapine 
Trade-off between 
benefits / harms2 
Unknown 
effectiveness 
Trade-off between 
benefits / harms2 
Trade-off between 
benefits / harms2 
   
Olanzapine 
Unknown 
effectiveness 
Unknown 
effectiveness 
 Likely beneficial    
Quetiapine 
Unknown 
effectiveness 
Unknown 
effectiveness 
 
Likely ineffective 
or harmful 
   
Antidepressants  
Mirtazapine 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
     
Trazodone 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
     
Calcium channel 
blocker 
 
Nimodipine 
Trade-off between 
benefits / harms 
Trade-off between 
benefits / harms 
Likely beneficial2     
Nicardipine 
Unknown 
effectiveness 
Unknown 
effectiveness 
     
Nifedipine 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
     
Verapamil 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
     
Flunarizine  
Likely ineffective 
or harmful 
     
Amantadine 
Unknown 
effectiveness 
Unknown 
effectiveness 
 
Likely ineffective 
or harmful 
   
Clonidine 
Unknown 
effectiveness 
Unknown 
effectiveness 
     
Glutethimide 
Unknown 
effectiveness 
Unknown 
effectiveness 
     
L-
tryptophan/pyri
doxine 
Unknown 
effectiveness 
Unknown 
effectiveness 
     
Theophylline 
Unknown 
effectiveness 
Unknown 
effectiveness 
     
Isoniazid 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
     
Methazolamide 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
     
3,4-
diaminopyridine 
 
Likely ineffective 
or harmful 
     
Botulinum toxin 
A 
Trade-off between 
benefits / harms2 
Trade-off between 
benefits / harms2 
 Likely beneficial2    
Combination 
therapy 
 
Propranolol + 
Primidone 
Likely beneficial1   Likely beneficial1    
Surgical treatment 
Unilateral 
Thalamic DBS 
Trade-off between 
benefits / harms2 
Trade-off between 
benefits / harms2  Likely beneficial
3    
Bilateral 
Thalamic DBS   
Trade-off between 
benefits / harms3 
Likely ineffective 
or harmful 
   
Subthalamic 
nucleus DBS    
Trade-off between 
benefits / harms3 
   
Unilateral 
Thalamotomy 
Trade-off between 
benefits / harms3 
Trade-off between 
benefits / harms3 
Trade-off between 
benefits / harms3 
Likely ineffective 
or harmful 
   
Bilateral 
Thalamotomy 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
Likely ineffective 
or harmful 
    
Gamma knife 
surgery 
Unknown 
effectiveness 
Unknown 
effectiveness 
     
  
Head Tremor 
Pharmacologic treatment 
Propranolol Likely beneficial Likely beneficial      
Botulinum toxin 
A 
Trade-off between 
benefits / harms 
Trade-off between 
benefits / harms  
Likely 
beneficial2 
   
Surgical treatment 
Unilateral 
Thalamic DBS 
Unknown 
effectiveness 
Unknown 
effectiveness      
Bilateral 
Thalamic DBS   
Unknown 
effectiveness 
Likely ineffective 
or harmful 
   
Unilateral 
Thalamotomy 
       
Gamma knife 
surgery 
       
Voice Tremor 
Pharmacologic treatment 
Botulinum toxin 
A 
Trade-off between 
benefits / harms 
Trade-off between 
benefits / harms  
Trade-off between 
benefits / harms2    
Surgical treatment 
Unilateral 
Thalamic DBS 
Unknown 
effectiveness 
Unknown 
effectiveness      
Bilateral 
Thalamic DBS   
Unknown 
effectiveness 
Likely ineffective 
or harmful 
   
Unilateral 
Thalamotomy 
       
Gamma knife 
surgery 
       
Orthostatic Tremor 
Pharmacologic treatment 
Clonazepam   
Likely 
beneficial2 
    
Behavioral Techniques and Physical Therapy 
Relaxation 
therapies 
  
Likely 
beneficial4 
    
Reducing 
emotional stress 
  
Likely 
beneficial4 
    
Using the less 
disabled hand   
Likely 
beneficial4 
    
Using wrist 
weights 
  
Likely 
beneficial4 
    
Minimizing 
exposure to 
tremorogenic 
foods and drugs 
  
Likely 
beneficial4 
    
Standardized categories: Beneficial interventions are highlighted green; Likely beneficial interventions 
are highlighted yellow; Trade-off between benefits/harms interventions are highlighted orange; 
Interventions of Unknown effectiveness are highlighted in grey. Likely ineffective or harmful 
interventions are highlighted in red. 
1. when monotherapy does not sufficiently reduce tremor 
2. as second-line treatment 
3. refractory to medical therapies 
4. in patients with less disabling tremor 
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Appendix 1: Criteria applied to select eligible articles for appraisal 
 
 Inclusion criteria Rationale for the criteria Exclusion criteria 
1. 
Article identifying itself as “guidelines”, 
“recommendations”, “practice parameters”, “practice 
guidelines”, “standards of practice”, “standard 
treatment”, “algorithm”, “consensus” or “expert opinion” 
Fulfill the purpose of this review 
 
Articles that do not meet the 
terms mentioned in the 
inclusion criteria, or that 
concern specific forms of 
tremor other than the subject 
of this review  
 
2. 
Title or abstract includes one or more of the following 
terms: “tremor”, “essential tremor”, “action tremor”, 
“postural tremor”, “kinetic tremor”, “intention tremor”, 
“familial tremor”, “benign tremor”, “movement 
disorders”, “neurological diseases” 
3. 
Guidelines that include treatment of Essential Tremor, 
either non pharmacological, medical or surgical. 
Only articles that focus on the 
subject of this review were 
included. 
Guidelines that do not focus 
on treatment of Essential 
Tremor 
4. All languages included Identify as many existing 
guidelines or recommendations as 
possible, including international, 
national or local ones that focus 
on the subject of this review. 
5. 
Produced at international, national or local levels by 
medical associations or governmental bodies 
6. All available publications until Jan 2016 were included 
7. 
Publication type: practice guidelines, consensus statement, 
expert opinion 
Practice guidelines may be 
developed by government 
agencies at any level, institutions, 
organizations such as professional 
societies or governing boards, or 
by the convening of expert panels 
1, with the purpose of guiding 
decisions in clinical practice. 
Publication type: exclusively 
systematic reviews of the 
evidence, research articles, 
clinical trials, case reviews or 
consensus statements without 
supporting evidence 
 
1 Source:http://www.nlm.nih.gov/mesh/pubtypes.html 
 
  
Appendix 2: Data from AGREE II evaluation with scores for each item 
AAN 2005 AAN 2011 AIAN 2011
DISMO V-SIN 
2013
SWEMO DIS 
2014
DGN 2012 JSNT 2011 CAN 2009
1 5,00 5,00 2,00 7,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
2 6,00 6,00 3,00 6,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
3 5,00 4,00 2,33 6,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
4 5,00 6,00 3,67 5,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
5 1,00 1,00 1,00 1,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
6 6,67 6,33 1,00 5,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
7 5,67 6,00 1,00 7,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
8 6,00 6,00 1,00 7,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
9 4,33 5,00 1,33 6,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
10 1,67 1,33 1,00 6,33 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
11 6,67 6,33 5,33 6,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
12 6,67 6,67 2,67 7,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
13 2,33 5,00 1,00 6,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
14 1,33 1,00 1,00 1,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
15 6,67 6,33 4,00 7,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
16 6,33 6,00 6,00 6,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
17 6,67 6,33 6,67 6,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
18 1,00 1,00 1,00 1,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
19 1,67 2,33 2,33 2,33 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
20 1,00 1,00 1,00 1,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
21 1,00 1,00 1,00 1,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
22 4,00 6,00 1,00 3,33 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
23 1,00 6,33 5,33 5,67 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
4,00 5,00 2,00 6,00 #DIV/0! #DIV/0! #DIV/0! #DIV/0!
Domain 1. Scope and Purpose
Domain 5. Applicability
O verall assessment
Guideline Developer
Domain 6. Editorial Independence
Domain 4. Clarity of Presentation
Domain 3. Rigor of Development
Domain 2. Stakeholder Involvement
AAN: American Academy of Neurology; AIAN: Annals of Indian Academy of Neurology; DISMOV-SIN: Italian Movement 
Disorders Association; DGN: German Society of Neurology; SWEMODIS: Swedish Movement Disorders Society; JSNT: 
Japanese Society of Neurological Therapeutics; CAN: Chinese Association of Neurology. 
Appendix 3: Categories of effectiveness by the BMJ Clinical Evidence Data  
 
Intervention Icon Description 
Beneficial  
 
 For which effectiveness has been demonstrated by clear evidence 
from systematic reviews, RCTs, or the best alternative source of 
information and for which expectation of harms is small compared 
with the benefits. 
Likely to be 
beneficial  
 
For which effectiveness is less well established than for those listed 
under “beneficial”. 
Trade-off 
between benefits 
and harms 
 For which clinicians and patients should weigh up the beneficial 
and harmful effects according to individual circumstances and 
priorities. 
Unknown 
effectiveness  
 
For which there are currently insufficient data or data of inadequate 
quality. 
Likely to be 
ineffective or 
harmful  
 
For which ineffectiveness or associated harm has been 
demonstrated by clear evidence. 
 
http://clinicalevidence.bmj.com/x/set/static/cms/nuts-and-bolts.html 
BMJ Group. Clinical Evidence Handbook. BMJ Evidence Centre, June 2011 
 
